CDTX — Cidara Therapeutics, Inc.

Cidara Therapeutics Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Cidara reported a milestone payment of $45 million, triggered by the initiation of the Phase III ANCHOR trial, which will be recognized in Q4.
• The company ended Q3 with approximately $476 million in cash, ensuring full funding for the Phase III development program under various scenarios.

2. Strategic Updates and Business Highlights

• CD388 Development: The lead candidate, CD388, has entered Phase III development six months ahead of schedule, following FDA feedback that led to an expanded patient population for the trial to include healthy adults over 65.
• Breakthrough Therapy Designation: CD388 received breakthrough therapy designation from the FDA, enhancing access to regulatory guidance and potentially accelerating the approval process.
• BARDA Funding: Cidara secured a $339 million award from BARDA to support manufacturing and clinical development, with an initial $58 million allocated for the first 24 months.
• Cloudbreak Platform: The proprietary platform aims to develop novel drug-Fc conjugates (DFCs) for treating serious diseases, positioning CD388 as a long-acting antiviral for influenza prevention.

3. Forward Guidance and Outlook

• The ANCHOR trial is expected to enroll 6,000 participants across 150 sites, with over 50% enrollment achieved by early November. Target enrollment completion is anticipated by December.
• An interim analysis is planned for late Q1 2026 to assess the need for additional participants based on event rates and powering assumptions.
• Cidara plans to host a virtual R&D Day on December 15 to provide further updates on CD388 and market research insights.

4. Bad News, Challenges, or Points of Concern

• Vaccination Rates: There are concerns regarding declining flu vaccination rates, which could impact the study's event rates and overall efficacy results.
• Manufacturing Scale-Up: While the initial manufacturing capacity at WuXi is set for 5 million doses annually, scaling up to meet potential demand remains a challenge, particularly as the company transitions to a commercial vial formulation.
• Event Rate Projections: The timing of enrollment completion in December may affect the expected event rates during the flu season, which could influence the trial's outcomes.

5. Notable Q&A Insights

• The interim analysis will not provide efficacy data but will assess whether the trial's powering assumptions are met.
• The inclusion of healthy individuals over 65 is expected to facilitate faster enrollment and potentially increase the event rate due to lower protection levels in this demographic.
• Cidara is exploring the potential for CD388 to address pandemic influenza strains, with ongoing studies demonstrating efficacy against H5N1 strains.
• The company remains vigilant regarding the evolving landscape of flu vaccination rates, which could impact the trial's dynamics and outcomes.

Overall, Cidara Therapeutics is making significant strides in the development of CD388, with strong financial backing and strategic initiatives, though challenges related to vaccination rates and manufacturing scalability remain pertinent.